Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuroprotective Agents (toxicity)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 51.
[20-40] [0 - 20][0 - 50][40-50][40-60]

Ident.	Authors (with country if any)	Title
002483 (2009)	Robert G. Hart [États-Unis] ; Lesly A. Pearce ; Bernard M. Ravina ; Toby C. Yaltho ; John R. Marler	Neuroprotection trials in Parkinson's disease: systematic review.
002486 (2009)	Nir Giladi [Israël] ; Joseph Tal ; Tali Azulay ; Oliver Rascol ; David J. Brooks ; Eldad Melamed ; Wolfgang Oertel ; Werner Poewe [Autriche] ; Fabrizio Stocchi ; Eduardo Tolosa	Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
002931 (2010)	Richard Dodel [Allemagne] ; Annika Spottke ; Alexander Gerhard ; Alexander Reuss ; Sylvia Reinecker ; Nicole Schimke ; Claudia Trenkwalder ; Friederike Sixel-Döring ; Birgit Herting ; Christoph Kamm ; Thomas Gasser ; Martin Sawires ; Felix Geser ; Martin Köllensperger ; Klaus Seppi ; Manja Kloss ; Martin Krause ; Christine Daniels ; Günther Deuschl ; Silke Böttger ; Markus Naumann ; Axel Lipp ; Doreen Gruber ; Andreas Kupsch ; Yansheng Du ; Federico Turkheimer ; David J. Brooks ; Thomas Klockgether ; Werner Poewe [Autriche] ; Gregor Wenning ; Carmen Schade-Brittinger ; Wolfgang H. Oertel ; Karla Eggert	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).
002A11 (2010)	Rodger J. Elble ; Oksana Suchowersky [Canada] ; Stephanie Shaftman ; William J. Weiner ; Peng Huang ; Barbara Tilley	Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
002A37 (2010)	Michele Terzaghi ; Valter Rustioni ; Raffaele Manni ; Claudio Pacchetti ; Roberta Zangaglia ; Maria Ossola	Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: immediate efficacy of rivastigmine.
002A62 (2010)	Caroline M. Tanner [États-Unis]	Advances in environmental epidemiology.
002A64 (2010)	Christian Wider [États-Unis] ; Tatiana Foroud ; Zbigniew K. Wszolek	Clinical implications of gene discovery in Parkinson's disease and parkinsonism.
003061 (2011)	Robert A. Hauser [États-Unis] ; Peggy Auinger	Determination of minimal clinically important change in early and advanced Parkinson's disease.
003149 (2011)	Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit ; P Nar Unsalan ; Hilal Horozoglu ; Nese Tuncer ; Aynur Feyzioglu ; Dilek Ince Gunal ; Gorsev G. Yener ; Raif Cakmur ; Huseyin A. Sahin ; Murat Emre	The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
003392 (2011)	Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill ; Alan R. Crossman ; Paula Ravenscroft	Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
003403 (2011)	Peter Jenner [Royaume-Uni] ; J William Langston	Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
003429 (2012)	Charles S. Venuto [États-Unis] ; Andrew Mcgarry ; Qing Ma ; Karl Kieburtz	Pharmacologic approaches to the treatment of Huntington's disease.
003626 (2012)	Johannes R. Streffer [Belgique] ; Igor D. Grachev ; Cheryl Fitzer-Attas ; Baltazar Gomez-Mancilla ; Babak Boroojerdi ; Juliana Bronzova ; Susanne Ostrowitzki ; Stephen J. Victor ; Paulo Fontoura ; Robert Alexander	Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
003732 (2012)	Erwan Bezard [France] ; Zhenyu Yue [États-Unis] ; Deniz Kirik [Suède] ; Maria Grazia Spillantini [Royaume-Uni]	Animal Models of Parkinson’s Disease: limits and relevance to neuroprotection studies
003780 (2013)	Anthony E. Lang [Canada] ; Eldad Melamed ; Werner Poewe [Autriche] ; Olivier Rascol	Trial designs used to study neuroprotective therapy in Parkinson's disease.
003784 (2013)	Pankaj A. Agarwal [Canada] ; A Jon Stoessl	Biomarkers for trials of neuroprotection in Parkinson's disease.
003787 (2012)	Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Antongiulio Gallina [Italie] ; Yingfei Wang [États-Unis] ; Jeannette N. Stankowski [États-Unis] ; Barbara Picconi [Italie] ; Valina L. Dawson [États-Unis] ; Ted M. Dawson [États-Unis]	New Synaptic and Molecular Targets for Neuroprotection in Parkinson’s Disease
003A05 (2013)	C Warren Olanow [États-Unis] ; Jose A. Obeso ; Fabrizio Stocchi	The vatican meeting on neuroprotection for Parkinson's disease.
003A06 (2013)	Fabrizio Stocchi [Italie] ; C Warren Olanow	Obstacles to the development of a neuroprotective therapy for Parkinson's disease.
003A07 (2013)	C Warren Olanow [États-Unis] ; Patrik Brundin	Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
003A96 (2013)	Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François Tison	Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024